Where does Hinova Pharmaceuticals Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Hinova Pharmaceuticals Inc. ranks #24,473 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Hinova Pharmaceuticals Inc. hold?

Hinova Pharmaceuticals Inc. holds 11 US utility patents granted between 2016 and 2025, spanning 5 technology areas.

What is Hinova Pharmaceuticals Inc.'s Innovation Score?

Hinova Pharmaceuticals Inc. has an Innovation Score of 44.0 out of 100 (top 27% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Hinova Pharmaceuticals Inc. focus on?

Hinova Pharmaceuticals Inc.'s top technology area is C07D (Heterocyclic Compounds) with 11 patents, ranking #741 of 3,165 assignees active in that subclass. Grants appear in 5 CPC subclasses total.

Is Hinova Pharmaceuticals Inc.'s patent grant rate increasing or decreasing?

Hinova Pharmaceuticals Inc.'s recent grant velocity is +133% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Hinova Pharmaceuticals Inc.'s patents?

Hinova Pharmaceuticals Inc.'s patents average 12.6 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Hinova Pharmaceuticals Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Hinova Pharmaceuticals Inc.

USPTO PatentsView assignee record - 11 granted patents across 5 technology areas, recorded in grant years 2016–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Hinova ranks #24,473 of 49,997 tracked US assignees by granted-patent volume, with 11 patents across 5 technology areas.

#24,473
of 49,997 US assignees by volume: Top 27%
by Innovation Score (44.0/100): 12.6
avg claims per patent: +133%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R24473 · Foreign Corporation #24,473 · 11 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 11 grants
MID-PACK #24,473/49,997
PHOTO-FINISH Hestia Power
CPC-NARROW C07D · 5 areas
INNOV-PAR 44.0/100
CLAIMS-RICH 12.6 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-SURGE +133% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Hestia Power Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Hinova’s 44.0 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 8.6 pts (20%) Velocity 20.0 pts (45%) Breadth 7.9 pts (18%) Claim depth 7.5 pts (17%)

Qualcomm Incorporated · highest

85
Carlisle Constructio… · near

44
Directa Plus S p A · near

44
Lumentum Japan · near

44
Hinova Pharmaceuticals · this assignee

44
Peloton Technology · near

44
3D Lighting… · lowest

7

What this shows Hinova's Innovation Score is 44.0/100 (top 27% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Hinova?

Each dot is one of Hinova’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Hinova’s own 12.6 claims/patent is ABOVE the 9.6 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Hinova vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Hinova's grants concentrate

Hinova Pharmaceuticals Inc. is a focused PatentsView assignee: 5 CPC subclasses with 100% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2023 (3 grants) versus a trough of 1 in 2016. By volume, Hinova sits between Hestia Power Inc. and Hollymatic Corporation.

Hinova's three-year grant acceleration

Hinova Pharmaceuticals Inc. shows 7 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Hestia Power

11
HH Medical

11
Highspot

11
Himolla PolstermÖ…

11
Hispano Suiza

11
Hithium Tech HK

11
Hokuto

11
Hollymatic

11
Hinova Pharmaceut… ◀

11

What this shows Hinova holds 11 patents at rank #24,444, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Hinova

By rank, the assignees closest to #24,444 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in Hinova's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Hinova, neither rank-band nor same-CPC leaders (those blocks stay above). In C07D (Heterocyclic Compounds), Hinova ranks #741 of 3,165 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (44 here).

Peloton Technology, Inc. 44 Directa Plus S.p.A. 44 Carlisle Construction Materials, LLC 44 Lumentum Japan, Inc. 44

Hinova's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

44 Top 27% higher than 73% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

Hinova Pharmaceuticals Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	1	9.1%
2017	1	9.1%
2019	1	9.1%
2022	1	9.1%
2023	3	27.3%
2024	3	27.3%
2025partial year	1	9.1%

Which technologies does Hinova Pharmaceuticals Inc. patent most?

C07D - Heterocyclic Compounds 11

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 10

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 5

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 4

C07C - Acyclic OR Carbocyclic Compounds 1

Top 5 of 5 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Hinova Pharmaceuticals Inc.'s patent record in context - here's where to go next.

Hinova Pharmaceuticals Inc.'s lead technology class is C07D (Heterocyclic Compounds), 100% of its portfolio - see every assignee active in that class. Explore C07D
Ranked #24,473 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Hinova Pharmaceuticals Inc. against Hestia Power Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 44.0/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.